Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$3.02
$0.04(1.09%)
At close: 4:00 PM EST
$3.02
$0.04(1.09%)
Day’s Range― - ―
52-Week Range$1.11 - $5.74
Previous CloseN/A
Volume32.66K
Average Volume (3M)1.09M
Market Cap
$23.74M
Enterprise Value-$4.32B
Total Cash (Recent Filing)$10.12B
Total Debt (Recent Filing)$78.54M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding11,304,697
10 Day Avg. Volume342,221
30 Day Avg. Volume1,088,816
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-182.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit944.59K
Enterprise Value/Ebitda242.88
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI Platform (predictBBB LQM)Lantern’s expansion of predictBBB into an on‑demand Large Quantitative Model is a durable technical asset that can lower molecular characterization costs, accelerate candidate triage, and be monetized as a SaaS offering. That capability creates a repeatable commercial pathway separate from drug sales and strengthens long‑term R&D differentiation.
WithZeta.ai Commercial StrategywithZeta.ai’s public demos and management guidance toward licensing/subscriptions point to an intentional move to recurring software revenues. If adopted, this diversifies cash flow beyond one‑off deals, leverages core AI IP, and supports sustainable funding for clinical programs by creating non‑dilutive, repeatable income streams over months to years.
Clinical And Regulatory ProgressMultiple clinical advances and regulatory clearances materially reduce technical risk across the portfolio. Completed enrollments, a measurable benefit rate in early data, IND clearance and orphan status increase the probability of partnerships, regulatory paths, and eventual commercialization, improving the firm’s long‑term de‑risking profile.
Bears Say
No Revenue BaseLantern currently lacks product revenue, leaving operations wholly dependent on financing, partnerships, or milestone deals. That absence of recurring sales means long‑term sustainability hinges on future clinical success or commercial licensing, increasing execution and funding risk over the next several quarters to years.
Persistent Cash BurnRising operating cash outflows and worsening free cash flow create ongoing funding needs. Continued high burn constrains capacity to run multiple trials or scale platform commercialization without dilutive financings or material partnerships, pressuring strategic flexibility and potentially altering long‑term R&D priorities.
Commercialization And Partnership Execution RiskManagement acknowledges that revenue from AI platforms and licensing depends on customer adoption and partner deals. Execution risk—selling complex AI tools into pharma, converting beta partners, and securing sustainable contracts—is structural; failure to convert interest into contracts would leave the company dependent on volatile financing and slow growth.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $5.74 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $23.74M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 93 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 11,304,697 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.View all LTRN earnings summariesLTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Ownership Overview
19.04% Insiders
3.78% Mutual Funds
2.42% Other Institutional Investors
71.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---